The clinical study of atorvastatin calcium in the treatment of chronic congestive heart failure
10.3760/cma.j.issn.1008-6706.2017.12.024
- VernacularTitle:阿托伐他汀钙治疗慢性充血性心力衰竭患者临床研究
- Author:
Tiefeng ZHU
;
Weihua JIANG
;
Weiyi XU
- Keywords:
Heart Failure;
Atorvastatin Calcium;
Cholesterol;
Heart Function Tests
- From:
Chinese Journal of Primary Medicine and Pharmacy
2017;24(12):1845-1848
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy of atorvastatin calcium in the treatment of chronic congestive heart failure(CHF).Methods According to the order of admission with single and double,132 CHF patients were randomly divided into control group and study group,66 cases in each group.The control group was given routine treatment,and the study group was treated with atorvastatin calcium on the basis of routine treatment.The clinical efficacy was assessed.Before and after treatment,the serum TC level was measured,the left ventricular ejection fraction(LVEF) and heart left ventricular end diastolic diameter(LVDD),heart index(CI) were assessed by echocardiography.The adverse reactions during treatment were observed.Results The total effective rate of the study group was 92.42%,which was higher than 83.33% of the control group,the difference was statistically significant(x2=9.35,P<0.05).The serum TC of the study group after treatment was (3.24±0.75)mmol/L,which was lower than (4.70±0.86)mmol/L of the control group,the difference was statistically significant(t=8.96,P<0.05).The level of LVEF of the study group after treatment was (46.39±6.35)%,which was higher than (44.60±5.82)% of the control group,the difference was statistically significant(t=9.47,P<0.05).The levels of LVDD and CI were (47.06±5.39)mm and (2.60±0.62)L·min-1·m-1 respectively,which were lower than (49.53±6.17)mm and (2.97±0.69)L·min-1·m-1 of the control group,the differences were statistically significant(t=10.31,9.40,all P<0.05).There was no significant difference in adverse reactions between the two groups(x2=2.04,P>0.05).Conclusion Atorvastatin calcium in the treatment of CHF patients on the basis of routine treatment has better clinical effect.It can significantly reduce TC and significantly improve cardiac function,and has high safety.
